13F Holdings
中文EN

INMB Inmune Bio, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1711754 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY257.1%
TTM net income YoY-9.2%
TTM EPS YoY11.8%
Revenue 3-yr CAGR-48.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-94,766.0%
Net margin-91,866.0%
FCF margin—
EBITDA margin—

Returns

ROE-165.2%
ROA-127.7%
ROIC (approx.)-300.1%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets27.3%
Debt / equity0.00x
Current ratio3.55x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.49x
Accruals ratio-64.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$50,000$14,000$155,000$374,000$181,000
R&D expense$20.66M$33.17M$20.27M$17.07M$20.54M
SG&A expense$10.26M$9.48M$9.62M$9.26M$8.79M
Operating income-$47.38M-$42.63M-$29.74M-$25.95M-$29.15M
Interest expense$0$789,000$2.28M$2.01M$985,000
Pretax income$45.93M$42.08M$30.01M——
Net income-$45.93M-$42.08M-$30.01M-$27.30M-$30.34M
EBITDA-$47.30M————
EPS (basic)-1.86-2.11-1.67-1.52-1.88
EPS (diluted)-1.86-2.11-1.67-1.52-1.88
Weighted avg. shares (diluted)24.76M19.94M17.98M17.93M16.13M
Balance sheet
Cash & equivalents$24.75M$20.92M$35.85M$52.15M$74.81M
Receivables$4.28M$1.18M$1.91M——
Current assets$29.89M$22.66M$39.94M$64.67M$82.61M
PP&E, net$955,000————
Intangibles—$16.51M$16.51M$16.51M$16.51M
Total assets$32.35M$39.56M$57.00M$81.80M$99.94M
Current liabilities$8.42M$7.22M$18.46M$10.92M$4.36M
Short-term debt——$9.92M$5.00M$704,000
Long-term debt—$15.00M—$9.70M$15.00M
Total debt—$15.00M—$14.70M$15.70M
Total liabilities$8.83M$7.46M$18.86M$21.69M$19.72M
Shareholders' equity$23.52M$32.10M$37.34M$60.10M$80.22M
Net debt—-$5.92M—-$37.46M-$59.11M
Shares outstanding26.59M22.28M17.95M17.95M17.84M
Cash flow statement
Operating cash flow-$22.58M-$33.36M-$11.98M-$22.69M-$28.50M
Capital expenditure$1.04M————
Free cash flow-$23.62M————
Investing cash flow-$1.04M———-$15.00M
Financing cash flow$27.61M$18.21M-$4.22M$729,000$96.36M
Depreciation & amortization$84,000————
Stock-based compensation$9.91M$7.61M$7.37M$7.15M$4.80M

Free plan shows the latest 5 periods; Pro shows all 9 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.